SCHEMBL1198136

SCHEMBL1198136

Cc1nc(-c2cccc(C(F)(F)F)c2)sc1Cn1cc(C(=O)O)cn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
KLKB1 P03952 1/20 0.52
PPARA Q07869 4/20 0.50
PPARG P37231 3/20 0.50
PPARD Q03181 3/20 0.50
EGLN1 Q9GZT9 1/20 0.46
MAPT P10636 5/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
NR1H4 Q96RI1 1/20 0.44
HPGD P15428 1/20 0.44
GPR52 Q9Y2T5 1/20 0.43
KCNH2 Q12809 1/20 0.43
XDH P47989 1/20 0.43
PTPN1 P18031 1/20 0.42
PIN1 Q13526 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1199035 0.90 MAPT (0.57) ALDH1A1SMN1; SMN2KLKB1PPARAPPARG
SCHEMBL12875928 0.87 KLKB1 (0.56) ALDH1A1SMN1; SMN2KLKB1PPARDMAPT
SCHEMBL1198412 0.87 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2KLKB1PPARAPPARG
SCHEMBL1198840 0.86 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2PPARAPPARGPPARD
SCHEMBL1198826 0.86 KMT2A (0.48) ALDH1A1SMN1; SMN2KLKB1PPARAPPARG
SCHEMBL1198348 0.83 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2PPARAPPARGEGLN1
SCHEMBL1198880 0.83 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2PPARAPPARGEGLN1
SCHEMBL1198845 0.81 MEN1 (0.47) ALDH1A1SMN1; SMN2EGLN1MAPTMEN1
SCHEMBL1198763 0.81 MEN1 (0.47) ALDH1A1SMN1; SMN2EGLN1MAPTMEN1
SCHEMBL1198292 0.81 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ALDH1A1 1037/4885SMN1; SMN2 2057/4885KLKB1 3765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.